FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression - U.S. News & World Report

WEDNESDAY, Jan. 22, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had ... Read More

FDA approves nasal spray drug to treat depression - ConsumerAffairs

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray as the first and only monoth ... Read More

FDA approves first nasal spray for major depression disorder - KSAT.com

The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive disorder. Skip to main content Open Main Menu Navigation ... Read More

FDA approves first nasal spray treatment for severe depression - MSN

The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe depression. It is now the first-ever stand-alone therapy for treatment ... Read More

Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression

1. SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression. News release. Johnson & Johnson. January 21, 2025. Accessed January ... Read More

FDA Approves Benlysta Autoinjector for Pediatric Patients With Active Lupus Nephritis

The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with ... Read More

FDA Approves Johnson & Johnson’s Spravato for Treatment-Resistant Depression

The FDA has approved Johnson & Johnson’s (J&J) Spravato (esketamine) CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD). According to ... Read More

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression - Benzinga

FDA approves Spravato as the first monotherapy for adults with major depressive disorder unresponsive to two oral antidepressants. In clinical trials, 22.5% of Spravato patients achieved remission ... Read More

Main ingredient in new nose spray for depression might shock you - PIX11

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind medi… ... Read More

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression - Yahoo Finance

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treatment the first and only ... Read More